Member Info for Chelsea11

Thanks Berm.

So, 14 locations with a status of recruiting.

Big pharma will also know how to calculate ORR 😂

I do believe we’re on the cusp of entering H2 2024. Could be a very exciting 6 mths coming up.

Top posts from Ray & RW

Great news. Also narrows down the possibilities of the mab under investigation by the major pharma?

Scinv truly believes some posters here, give a fig about what he’s saying.

That takes quite a psychological condition to be fair.

Yep. Aligns to my view here that the market reaction to recent update was harsh. Not expecting fireworks just yet but hopefully a climb back to over 105 in the short term.

The global cancer monoclonal antibody market size $42B in 2021. Market expected to reach $57B by 2028 (IMARC Report 2023).

It’s reasonable to think that there are discussions ongoing re the out-licence of AvidiMab, given that in theory, it can be applied to any antibody.

That wouldn’t come cheap and might fill a few self-fund tins.

Let’s not post under the subject of Bermuda.

We all know Scinv is a joke and we can now move on.

He’s had a scinv-ful obviously!

Sounds like you’re on the cusp of re-investing C7.

Don’t be shy!

The other question being, which mab is it………….

Hmmmmm dunno, maybe.

If Genmab, why not name them given they already have one on the go.

Matt - “general information interview, nothing more”.

Well yes, if you’re purely coming from the angle of new data / deals, I’d agree.

However from an angle of wide promotion of the company and the science, the confident body language and potential to read between the lines of the future direction of Scancell, it’s far, far more than that for me.

Anyway, where’s knowlesi gone? 😂

Not a 5p valuation then.

Ironic isn’t it, that on the day Scancell announce a significant collaboration with a “Major Biotech”, there is one individual who wants to continue to insist that our CEO deliberately misleads investors.

Doesn’t seem to me like the Major Biotech shares that view!

Had to chuckle on reading the RNS. Only as recently as yesterday, there were posters moaning that if less presentations were attended, there would be more time to produce income. Bordering a LMAO moment.

Don’t agree IVS operate in a niche market. Smart manufacturing, automation and AI related production, is a rapidly growing industry and most definitely here to stay. It would not surprise me one bit if they have acquisition(s) in the pipeline already undergoing due diligence, that fit to that industry. Like I said, let’s wait and see what Q4 brings.

Guess we should compare notes in Q4 - potentially a Trading Update, acquisition news, Prelims and of course where the SP is at.

I get what you’re saying and don’t disagree with a lot of it. Had they squandered the Yotta cash though, it would be much, much worse here. It has happened to plenty of other companies where poor and early acquisitions have been made, when money is in the Bank. Recent examples where companies were awash with COVID related cash.

Trotsky - you make some valid points. Another angle though on the cash pile, is that they haven’t made any rash M&A decisions, which might have set the company back years. It’s not difficult to identify other companies that have made that mistake. Underwhelming I agree but if the mañana you mention is no longer than Q3 for an earnings / profit enhancing acquisition, they should soon be firing again. Market reaction today overly harsh imo.